On Jun 29, 2018, Raymond James Covered Five Prime Therapeutics (NASDAQ:FPRX) Rating.

June 29, 2018 - By Sarah Harris

During Q1 2018 the big money sentiment increased to 2.33. That’s change of 0.99, from 2017Q4’s 1.34. 21 investors sold all, 12 reduced holdings as Five Prime Therapeutics, Inc. ratio increased. 56 rose positions while 21 funds took positions. Funds hold 31.62 million shares thus 24.14% more from 2017Q4’s 25.47 million shares.

The Maine-based Schroder Investment Mngmt Group Inc has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Wellington Mgmt Gp Llp stated it has 0.02% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Bogle L P De accumulated 71,552 shs. Deutsche Commercial Bank Ag has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Jacobs Levy Equity, New Jersey-based fund reported 27,990 shs. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 2,495 shs. Ecor1 Cap Limited Liability Corporation stated it has 1.24 million shs or 2.14% of all its holdings. Millennium Ltd Liability Corp has invested 0.01% of its capital in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Great Point Partners holds 868,100 shs or 0% of its capital. State Bank Of America Corporation De, a North Carolina-based fund reported 100,532 shs. Dimensional Fund Advsr L P holds 0.01% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) or 1.04 million shs. Bb Biotech Ag holds 0.46% or 977,500 shs in its capital. State Common Retirement Fund stated it has 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Eventide Asset Ltd owns 0.08% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 105,000 shs. Virginia Retirement Sys Et Al stated it has 0.01% of its capital in Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

What’s Raymond James’s Current Rate of Five Prime Therapeutics (NASDAQ:FPRX)

On Thursday, 28 June was sent to investors and clients a note in which Raymond James has initiated coverage on shares of FPRX. The financial firm issued “Market Perform” rating on Five Prime Therapeutics (NASDAQ:FPRX)‘s stock.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

In total 8 analysts cover Five Prime Therapeutics (NASDAQ:FPRX). “Buy” rating has 4, “Sell” are 0, while 4 are “Hold”. (NASDAQ:FPRX) has 50% bullish analysts. 8 are the (NASDAQ:FPRX)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Wednesday, February 28 the rating was maintained by BMO Capital Markets with “Outperform”. On Thursday, March 1 the company was maintained by Jefferies. On Thursday, February 15 Guggenheim maintained the shares of FPRX in report with “Buy” rating. On Wednesday, February 28 the stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Buy” rating given by Nomura.

FPRX is touching $15.61 during the last trading session, after increased 0.39%.Currently Five Prime Therapeutics, Inc. is downtrending after 37.93% change in last June 29, 2017. FPRX has 110,090 shares volume. The stock underperformed the S&P500 by 50.50%.

On August, 14 Five Prime Therapeutics, Inc. (NASDAQ:FPRX)’s earnings release is awaited by WallStreet, Zacks reports. EPS of $-1.45 is 8.23 % up from 2017’s $-1.58 EPS. Wall Street sees 130.16 % negative EPS growth as of August, 14.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics.The firm is worth $549.62 million. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.Last it reported negative earnings. The Company’s product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers.

For more Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news announced recently go to: Investorplace.com, Businesswire.com, Benzinga.com, Streetinsider.com or Benzinga.com. The titles are as follows: “5 Top-Ranked High-Beta Stocks to Play the Roaring Market” announced on June 07, 2018, “Five Prime Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference” on June 05, 2018, “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” with a publish date: June 01, 2018, “JPMorgan Starts Five Prime Therapeutics (FPRX) at Neutral” and the last “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.